Barclays
DCOY

Barclays’s Decoy Therapeutics DCOY Stock Holding History

Barclays’s Portfolio DCOY Stock Details DCOY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-45
Closed -$7.19K – 5710
2025
Q2 		$7.19K Buy
+45
New +$6.33K ﹤0.01% 4939
2019
Q2 		– Hold
0
– – – 7242
2019
Q1 		– Hold
0
– – – 7299
2018
Q4 		– Hold
0
– – – 7297
2018
Q3 		– Hold
0
– – – 7364
2018
Q2 		– Hold
0
– – – 7249
2018
Q1 		– Hold
0
– – – 7304
2017
Q4 		– Hold
0
– – – 7089
2017
Q3 		– Hold
0
– – – 7021
2017
Q2 		– Hold
0
– – – 6194
2017
Q1 		– Hold
0
– – – 6495
2016
Q4 		– Hold
0
– – – 5500
2016
Q3 		– Hold
0
– – – 5714
2016
Q2 		– Hold
0
– – – 5980
2016
Q1 		– Hold
0
– – – 6003
2015
Q4 		– Hold
0
– – – 5692
2015
Q3 		– Hold
0
– – – 7023
2015
Q2 		– Hold
0
– – – 6817
2015
Q1 		– Hold
0
– – – 6990

Other funds holding DCOY

ASN
Advisory Services Network Atlanta, Georgia $8.83B AUM 38.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Barclays's DCOY Position: Q3 2025 in Review

Barclays sold out of Decoy Therapeutics (DCOY) in Q3 2025, closing a stake of 45 shares — an estimated $7.19K sold.

Barclays first reported a position in DCOY in Q2 2025 and held it in 1 quarter. The position peaked at $7.19K in Q2 2025. 3 funds tracked by Wall St. Rank hold DCOY as of Q3 2025.

  • Barclays reported no remaining Decoy Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Barclays sold 45 Decoy Therapeutics shares in Q3 2025, an estimated $7.19K.
  • Barclays first reported a position in Decoy Therapeutics in Q2 2025 and held it in 1 quarter.
  • Barclays's Decoy Therapeutics position peaked at $7.19K in Q2 2025.
  • 3 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q3 2025.

Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.